Latest news and press releases about Hoth Therapeutics, Inc. (HOTH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D.
Price
| Price | $0.80 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.22 |
| EV / EBITDA | -0.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -202.73% |
| Return on Invested Capital | -180.48% |
| Return on Assets | -164.00% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ASBP · BCTX · CRIS · DARE · ENTO · FBLG · LEXX
Explore sector: Healthcare · Biotechnology
More sections of HOTH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks